We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Drug Products
Books
FDAnews Books Library
Events
Form 483s Database
Subscription Newsletters
Free Newsletters
Webinar Training Pass
Device Products
Books
FDAnews Books Library
Events
Form 483s Database
Subscription Newsletters
Free Newsletters
Webinar Training Pass
Clinical Products
Advertising
White Papers
Contact Us
About Us
COVID-19
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Daniel J. Lahar
Daniel J. Lahar
Products
PRODUCTS
Clinicon Corp.
Daniel J. Lahar
Price:
$117.00
View
Dental Engineering Laboratories, LLC
Daniel J. Lahar
Price:
$117.00
View
Emerge Diagnostics, Inc.
Daniel J. Lahar
and
Juanj N. Wu
Price:
$117.00
View
Sotera Wireless, Inc.
Daniel J. Lahar
Price:
$117.00
View
Scantibodies Laboratory, Inc.
Daniel J. Lahar
Price:
$117.00
View
International Medical Development, Inc.
Daniel J. Lahar
Price:
$117.00
View
Shenzhen Dongdixin Technology Co., Ltd.
Daniel J. Lahar
Price:
$117.00
View
Ulthera, Inc.
Daniel J. Lahar
Price:
$117.00
View
Microfit, Inc.
Daniel J. Lahar
Price:
$117.00
View
James Consolidated, Inc.
Daniel J. Lahar
Price:
$117.00
View
View All Products by Daniel J. Lahar
Upcoming Events
07
Apr
FDA CDS Software Regulation: The Latest Guidance on Clinical Decision Support Software
08
Apr
PART 4: Clinical Trials in the Era of COVID-19 - The Changes You Need to Make Now
10
Apr
EU-MDR: Are You Ready? Part II: Tips for Assessing Your Readiness Prior to Notified Body Review
16
Apr
Medical Device Change Management
21
Apr
FDA’s Regulation of Digital Health Wearables & Sensors
Featured Products
Biological Risk Evaluation and Management for Medical Devices
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
Featured Stories
Gilead Begins Remdesivir Trials in the UK
FDA Clears First Coronavirus Antibody Test for Use During Pandemic
ElectroCore Seeks EUA for Vagus Nerve Stimulation Therapy
Emergent BioSolutions Partners with HHS for Plasma-Derived COVID-19 Treatment
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
